Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer

  Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive

 Former SeraCare CEO and Millipore Executive to Guide Strategic Direction of
                Life Sciences Services and Technology Company

Business Wire

BILLERICA, Mass. -- April 15, 2013

Aushon BioSystems, which provides a range of products and services that drive
the development of innovative life sciences diagnostics and therapies, today
announced the appointment of Susan Vogt as chief executive officer. Vogt
brings more than 30 years of experience in the global life science research,
pharmaceutical, biotech and clinical diagnostics markets to her new role.
Founder and former CEO Pete Honkanen will assume the role of chief operating
officer and continue as a board director.

Vogt's experience includes leadership roles at both small and large private
and public companies. Most recently, Vogt led the turnaround of diagnostics
reagents company SeraCare Life Sciences as president and CEO, where she
successfully re-listed the company on NASDAQ and returned the company to
growth and profitability. Previously, Vogt held numerous senior level
positions at Millipore Corporation, including corporate officer and president
of the company’s biopharmaceutical division. She currently serves as
non-executive director of TAP BioSystems, and has previously served on the
board of directors and advisory boards of a number of other private and
publicly-held companies. Vogt holds an MBA from Boston University and a BA
from Brown University.

“With sound technology, an elegant, easy-to-use platform and a strong customer
base, Aushon is well-positioned to lead the market as the demand for
multiplexing in the life sciences continues to grow,” said Vogt. “Our
technology enables research that’s critical to the development of both
therapeutics and diagnostics, and I look forward to driving the company’s
future growth.”

Aushon provides a suite of multiplex immunoassay products and services for the
discovery and development of the biomarkers necessary to enable personalized
medicine innovation. Multiplexing involves simultaneously measuring and
comparing multiple proteins – an improvement over today’s standard which
measures one at a time. Fueled by a growing market for multiplexing, Aushon
recently announced an anticipated 30 percent year-over-year revenue growth in
2013 and added Thomas Mac Mahon, former president and CEO of Laboratory
Corporation of America^® Holdings (LabCorp^®), to its board of directors.

“Susan is joining Aushon at an exciting time, as we’re expanding to meet
increasing demand for our technologies and services by pharmaceutical, biotech
and other life sciences research organizations,” said Honkanen. “Her
appointment is further evidence of Aushon’s momentum in helping our customers
drive the development of new tests and therapies, enabling personalized
medicine and, ultimately, better healthcare for patients.”

About Aushon

Aushon BioSystems, Inc. provides a comprehensive suite of multiplex
immunoassay products and services for protein biomarker discovery,
development, and analysis to leading pharmaceutical, biotechnology, academic
and diagnostic clients worldwide. Our unique combination of proprietary
microarray printing, extensive biomarker content, and our innovative Cira
immunoassay platform deliver exceptional performance, quality, and reliability
to accelerate preclinical and clinical biomarker research. Our customers, who
include nine of the top 10 pharmaceutical companies, trust Aushon to supply
the most reliable biomarker data available, lowering costs and improving
research productivity. Based in Billerica, Mass., Aushon is privately-held and
its investors include North Bridge Venture Partners.


Lois Paul and Partners
Siobhan Nguyen, 617-986-5784
Press spacebar to pause and continue. Press esc to stop.